Ippokratio General Hospital Of Thessaloniki
Thessaloniki, Greece
Not recruiting
Study Comparing Brinzolamide and Timolol Eye Drops for Patients with Glaucoma or Ocular Hypertension
Verified siteRegistered drug
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of two different eye drop treatments for patients with Glaucoma and Ocular Hypertension. These conditions involve increased pressure inside the eye, which can lead to vision problems if not managed properly. The study will compare a new generic combination of eye drops containing Brinzolamide and Timolol with an existing product called Azarga, which also contains the same active ingredients.
The purpose of the study is to determine if the new generic eye drops are as effective and well-tolerated as the Azarga eye drops in reducing eye pressure. Participants in the study will be randomly assigned to use either the generic eye drops or Azarga. The study will be conducted in a way that neither the participants nor the observers know which treatment is being used, to ensure unbiased results.
Throughout the study, participants will use the eye drops as directed and attend regular follow-up visits to monitor their eye pressure and overall eye health. The study will last for several weeks, during which the average change in eye pressure will be measured and compared between the two groups. This will help determine if the new generic eye drops are a suitable alternative for managing eye pressure in patients with glaucoma or ocular hypertension.
The research process
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
8 criteria
- Must be a male or female, of any race, and at least 18 years old.
- Must have been diagnosed with either one or both eyes having open angle glaucoma (a type of eye condition that can lead to vision loss) or ocular hypertension (higher than normal pressure inside the eye). This can be either currently under treatment or not yet treated.
- Must be able to safely stop using all eye pressure-lowering medications and go through a period without them.
- Must have a best-corrected visual acuity of at least 20 out of 100 in both eyes. This means the best vision you can achieve with glasses or contact lenses.
- Females participating must either be unable to become pregnant (due to menopause, surgical procedures like removal of ovaries or uterus, or having tubes tied) or, if they can become pregnant and are sexually active, must use effective birth control methods during the study. These methods include hormonal birth control, devices placed inside the uterus, having a partner who has had a vasectomy, or choosing not to have sex.
- The investigator must expect that the eye pressure will stay controlled with treatment, without damage to the optic nerve or worsening of vision.
- Must be able to understand what the clinical trial involves and agree to come back for follow-up visits as required.
- Must be willing to provide written consent and agree to data protection before any trial-related procedures are done.
Who cannot join the trial?
7 criteria
- Patients with any other eye disease besides ocular hypertension or glaucoma cannot participate. Ocular hypertension means higher pressure inside the eye, and glaucoma is a condition that can damage the eye's optic nerve.
- Patients who have had eye surgery in the last 3 months are not eligible.
- Patients using other eye medications that might interfere with the study cannot join.
- Patients with severe allergies to the study medications are excluded.
- Pregnant or breastfeeding women cannot participate.
- Patients with uncontrolled medical conditions that might affect the study results are not eligible.
- Patients who are unable to follow the study procedures or attend all visits are excluded.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified Verified Laiko General Hospital Of Athens
Athens, GreeceVerified University General Hospital Attikon
Athens, Greece
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Brinzolamide and Timolol Eye Drops
are a combination medication used to lower high pressure inside the eye, which can occur in conditions like open-angle glaucoma or ocular hypertension. Brinzolamide works by reducing the production of fluid within the eye, while Timolol helps by decreasing the amount of fluid produced and improving fluid drainage. Together, they help to prevent damage to the optic nerve and loss of vision by maintaining a healthy eye pressure.
Azarga
is an eye drop medication that also combines Brinzolamide and Timolol. It is used to treat high eye pressure in patients with open-angle glaucoma or ocular hypertension. Like the generic combination, Azarga works by reducing the production of fluid in the eye and improving fluid drainage, helping to lower the pressure and protect the optic nerve from damage.
What is already known about the treatment
Brinzolamide and Timolol Eye Drops – This medication is administered as eye drops and is used to treat conditions like ocular hypertension and glaucoma. It is currently being studied in clinical trials to compare its effectiveness and tolerability against a reference product. The main therapeutic indication is to reduce elevated intraocular pressure, which is crucial in managing glaucoma and preventing vision loss. Brinzolamide works by inhibiting an enzyme called carbonic anhydrase, reducing fluid production in the eye, while Timolol is a beta-blocker that decreases fluid production and increases fluid outflow. This combination falls under the pharmacological classification of ophthalmic glaucoma agents.
Investigated diseases
Ocular Hypertension
Ocular hypertension occurs when the pressure inside the eye, known as intraocular pressure, is higher than normal. This condition does not cause any noticeable symptoms, which makes it difficult to detect without regular eye exams. Over time, if left untreated, the elevated pressure can lead to damage of the optic nerve. Unlike glaucoma, ocular hypertension does not involve any detectable changes in vision or damage to the optic nerve initially. It is considered a risk factor for developing glaucoma. Regular monitoring is essential to prevent progression to more serious conditions.
Glaucoma
Glaucoma is a group of eye conditions that damage the optic nerve, often due to high intraocular pressure. It is one of the leading causes of blindness for people over the age of 60. The most common form, open-angle glaucoma, progresses slowly and painlessly, often without noticeable symptoms until significant vision loss occurs. In some cases, individuals may experience peripheral vision loss, which can progress to tunnel vision. The damage caused by glaucoma is irreversible, making early detection crucial. Regular eye examinations are important for those at risk to prevent severe vision impairment.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506494-35-00Protocol codeBECRO/OV/BRINZOTIMEstimated enrolment234 patientsSponsorOmniVision GmbH
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?